Page last updated: 2024-08-24

3-iodobenzylguanidine and temozolomide

3-iodobenzylguanidine has been researched along with temozolomide in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bodoky, G; Pregun, I; Rácz, K; Tulassay, Z	1
Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS	1

Reviews

1 review(s) available for 3-iodobenzylguanidine and temozolomide

Article	Year
[Carcinoid tumors]. Orvosi hetilap, 2010, Nov-14, Volume: 151, Issue:46 Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Biomarkers, Tumor; Bronchial Neoplasms; Carcinoid Tumor; Chromogranin A; Clinical Trials as Topic; Dacarbazine; Early Detection of Cancer; Gastrointestinal Neoplasms; Heterocyclic Compounds; Humans; Hydroxyindoleacetic Acid; Lung Neoplasms; Organometallic Compounds; Prevalence; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Somatostatin; Temozolomide; Thalidomide; TOR Serine-Threonine Kinases; Treatment Outcome	2010

Article

Year

[Carcinoid tumors].

Orvosi hetilap, 2010, Nov-14, Volume: 151, Issue:46

Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Biomarkers, Tumor; Bronchial Neoplasms; Carcinoid Tumor; Chromogranin A; Clinical Trials as Topic; Dacarbazine; Early Detection of Cancer; Gastrointestinal Neoplasms; Heterocyclic Compounds; Humans; Hydroxyindoleacetic Acid; Lung Neoplasms; Organometallic Compounds; Prevalence; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Somatostatin; Temozolomide; Thalidomide; TOR Serine-Threonine Kinases; Treatment Outcome

2010

Other Studies

1 other study(ies) available for 3-iodobenzylguanidine and temozolomide

Article	Year
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. Bone marrow transplantation, 2013, Volume: 48, Issue:5 Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide	2013

Article

Year

5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.

Bone marrow transplantation, 2013, Volume: 48, Issue:5

Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Irinotecan; Male; Neuroblastoma; Outpatients; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Temozolomide

2013